NEW YORK, Jan 3, 2026, 15:55 ET — Market closed
- Pfizer shares last closed up 1.1% at $25.18 on Friday.
- Investors are watching early-January U.S. drug pricing moves and the policy spotlight on list-price increases.
- Next catalyst: Pfizer’s Feb. 3 quarterly update, with key U.S. jobs and inflation data due next week.
Pfizer Inc (NYSE: PFE) shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday.
The stock is starting 2026 with drug pricing back in focus, a recurring risk for big pharma that can weigh on sentiment. Drugmakers raised U.S. list prices on at least 350 branded medicines starting Jan. 1, with Pfizer leading with increases on about 80 drugs, including a 15% hike for its COVID vaccine Comirnaty, a report said.
The pricing debate lands as Pfizer tries to steady earnings after the post-pandemic drop in demand for its COVID products and as some products face patent cliffs. Pfizer forecast 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings per share of $2.80 to $3.00, a non-GAAP measure that strips out certain items such as acquisition-related charges.
In December, Pfizer said 2026 would bring headwinds tied to lower sales of its COVID vaccine and treatment, price cuts promised to the U.S. government and patent expirations on key drugs. “This stock is unlikely to break out of its current mid-20s price range until investors are convinced of a growth trajectory,” Bernstein analyst Courtney Breen said.
At Friday’s close, Pfizer was still well below its 52-week high of $27.69 set on Oct. 3, with a 52-week low of $20.91 marked on April 9, according to market data.
Technicians also track the stock’s moving averages as a read on momentum. Pfizer’s 50-day moving average sat around $25.14, roughly in line with the latest close, according to Barchart data.
Pfizer has argued its price actions are modest in aggregate. The company told Reuters its average 2026 list-price increase for innovative medicines and vaccines is below the overall rate of inflation, BioSpace reported.
Macro data is another near-term swing factor for rate-sensitive positioning across U.S. equities. Investors are gearing up for the Jan. 9 U.S. jobs report and the Jan. 13 consumer price index, while fourth-quarter earnings season ramps up in mid-January.
Before the next session on Monday, markets will also look ahead to the Federal Reserve’s Jan. 27-28 policy meeting for clues on the path of interest rates.
For Pfizer, the next known catalyst is Feb. 3, when it plans to issue its fourth-quarter and full-year 2025 performance report and host a conference call with analysts at 10:00 a.m. EST, the company said.
Investors are likely to focus on whether Pfizer reiterates its 2026 outlook and how management frames COVID-product demand, loss-of-exclusivity pressures and progress in its cost realignment program.
On the chart, traders often treat the $25 area as a near-term pivot after Friday’s close, with the 52-week range framing broader support and resistance.
Absent fresh company-specific news over the weekend, Pfizer shares may take early-week direction from the broader tape, drug-pricing headlines and the next round of U.S. economic data.
